Alpha 2.0
Login Register
» Authors » Roberta Volta

Roberta Volta

Explore the profile of Roberta Volta including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 84
Followers 0
Related Specialties
Pharmacology
Chemistry
Top 10 Co-Authors
Fabrizio Facchinetti
Gino Villetti
Valentina Cenacchi
Paola Puccini
Chiara Carnini
Silvia Catinella
Maurizio Civelli
Paola Caruso
Nadia Moretto
Alberta Leon
Published In
J Pharmacol Exp Ther
J Med Chem
Pharmacol Res
Pharmaceutics
Affiliations
Soon will be listed here.
Recent Articles
1.
Daily Intraperitoneal Administration of Rosiglitazone Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia
Aquila G, Regin Y, Murgia X, Salomone F, Casiraghi C, Catozzi C, et al.
Pharmaceutics . 2022 Jul; 14(7). PMID: 35890402
Thiazolidinediones (TZDs) are potent PPARγ agonists that have been shown to attenuate alveolar simplification after prolonged hyperoxia in term rodent models of bronchopulmonary dysplasia. However, the pulmonary outcomes of postnatal...
2.
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases
Carzaniga L, Amari G, Rizzi A, Capaldi C, De Fanti R, Ghidini E, et al.
J Med Chem . 2017 Dec; 60(24):10026-10046. PMID: 29200281
Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing enzyme involved in the pathogenesis of inflammatory disease, and its pharmacological inhibition has been shown to exert therapeutic efficacy in chronic obstructive pulmonary...
3.
CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window
Villetti G, Carnini C, Battipaglia L, Preynat L, Bolzoni P, Bassani F, et al.
J Pharmacol Exp Ther . 2015 Jan; 352(3):568-78. PMID: 25576073
CHF6001 [(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide] is a novel phosphodiesterase 4 (PDE4) inhibitor designed for use in pulmonary diseases by inhaled administration. Intratracheal administration of CHF6001 to ovalbumin-sensitized Brown-Norway rats suppressed the antigen-induced...
4.
Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases
Armani E, Amari G, Rizzi A, De Fanti R, Ghidini E, Capaldi C, et al.
J Med Chem . 2014 Jan; 57(3):793-816. PMID: 24400806
The first steps in the selection process of a new anti-inflammatory drug for the inhaled treatment of asthma and chronic obstructive pulmonary disease are herein described. A series of novel...
5.
1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity
Imbimbo B, Del Giudice E, Colavito D, DArrigo A, Dalle Carbonare M, Villetti G, et al.
J Pharmacol Exp Ther . 2007 Sep; 323(3):822-30. PMID: 17895400
Some nonsteroidal anti-inflammatory drugs has been shown to allosterically modulate the activity of gamma-secretase, the enzymatic complex responsible for the formation of beta-amyloid (Abeta). 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074) is a new...
6.
In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents
Imbimbo B, Del Giudice E, Cenacchi V, Volta R, Villetti G, Facchinetti F, et al.
Pharmacol Res . 2007 Feb; 55(4):318-28. PMID: 17292621
Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) may delay or prevent the onset of Alzheimer's disease (AD). A subset of NSAIDs, including flurbiprofen, has been shown to selectively inhibit the...